

REMARKS/ARGUMENTS

Applicants request entry of this amendment in accordance with 37 C.F.R. 1.312, and 37 C.F.R. 1.821. At the paragraph beginning at p. 36, line 20, the specification refers to the SEQ ID NOS in column 15 of Table 4 as SEQ ID NOS 135-17. As is apparent from Table 4, these should actually be SEQ ID NOS:135-137. Claims 2, 6, and 11 refer to the SEQ ID NOS occupying the seventh column of Table 3 as 69-87, 112, and 245-252. As is apparent from Table 3, the claims should refer to SEQ ID NOS:59-87, 112 and 245-252. Finally, claims 3, 7, and 11 refer to first, second, third, fourth, fifth and sixth segments of seven contiguous amino acids specified in a row of Table 4 as being SEQ ID NOS: 117-119, 120-122, 123-125, 126-128, 129-131 and 132-134 respectively. As is apparent from Table 4, the SEQ ID NOS appearing in these claims have been transposed and should read 120-122, 123-125, 126-128, 129-131, 132-134 and 135-137 respectively. The corrections are of obvious typographic errors in use of SEQ ID NOS. and do not raise issues of new matter or affect the merits.

Applicants also make of record that the legal representative of co-inventor Alan Wolffe (deceased) is Elizabeth Wolffe.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422

JOL:adm
60624452 v1